| Literature DB >> 21705972 |
Yang Gao1, Ruhui Zhang, Juan Zhang, Shang Gao, Wenxin Gao, Haifeng Zhang, Haotian Wang, Bing Han.
Abstract
The aim of the reported study was to optimize the extraction process for ganoderma triterpenes and to investigate the in vivo inhibitory effect of ganoderma triterpenes on the genesis and progression of oral cancer. Single-factor and orthogonal methods were used to investigate the effects of extraction solvent, solvent amount, extraction time, extraction temperature, and number of extractions, on the extraction rate for ganoderma triterpenes. A golden hamster model with cheek pouch dynamic canceration was established to receive oral treatment of ganoderma triterpenes water solution. Animals were continuously monitored, oral tissue samples were collected for histopathologic examination, and changes in the expression of VEGF (vascular endothelial growth factor) and Caspase-3 were detected by immunohistochemical methods. Optimization of the experimental conditions allowed the identification of the optimal extraction conditions: 90% ethanol as the extraction solvent, a solvent amount by the liquid-material ratio of 35 mL/g, extraction time of 2 h and extraction temperature of 80 °C. Under these conditions, the average extraction rate of ganoderma triterpenes was 1.09%. Tests in golden hamsters showed that compared with the model group during the same period, animals in the treatment group had better conditions, constantly larger number of normal cases shown by histopathologic results (P < 0.01), and consistently smaller numbers of cases with paraplasm (P < 0.05). Immunohistochemical results showed that compared with the model group, the treatment group had significantly lower (P < 0.05) rates of positive VEGF expression in the normal state, simple epithelial hyperplasia, epithelial dysplasia or squamous cell carcinoma disease stages. Caspase-3 expression showed a tendency toward a gradual increase with the worsening of disease severity in each group. Compared with the model group, the treatment group had significantly lower (P < 0.05) rates of positive Caspase-3 in the normal state, simple epithelial hyperplasia, epithelial dysplasia or squamous cell carcinoma disease grades. Using the optimized extraction process, ganoderma triterpenes could be extracted with high efficiency, and the results of animal tests showed inhibitory effects of ganoderma triterpenes on oral mucosa cancer.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21705972 PMCID: PMC6264449 DOI: 10.3390/molecules16075315
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Ursolic acid standard curve.
Figure 2Results of single-factor tests.
Factor levels.
| Factor level | A (%) | B (mL/g) | C (h) | D (°C) |
|---|---|---|---|---|
| 1 | 80 | 20 | 1.5 | 60 |
| 2 | 90 | 30 | 2 | 70 |
| 3 | 95 | 35 | 2.5 | 80 |
Results of orthogonal test.
| No. | A | B | C | D | Extraction rate (%) |
|---|---|---|---|---|---|
| 1 | 80 | 20 | 1.5 | 60 | 0.569 |
| 2 | 80 | 30 | 2 | 70 | 0.932 |
| 3 | 80 | 35 | 2.5 | 80 | 1.101 |
| 4 | 90 | 20 | 2 | 80 | 0.829 |
| 5 | 90 | 30 | 2.5 | 60 | 0.907 |
| 6 | 90 | 35 | 1.5 | 70 | 1.036 |
| 7 | 95 | 20 | 2.5 | 70 | 0.803 |
| 8 | 95 | 30 | 1.5 | 80 | 0.894 |
| 9 | 95 | 35 | 2 | 60 | 0.997 |
| 0.867 | 0.734 | 0.833 | 0.824 | ||
| 0.924 | 0.911 | 0.919 | 0.924 | ||
| 0.898 | 1.045 | 0.937 | 0.941 | ||
| 0.057 | 0.311 | 0.104 | 0.117 | ||
| 0.005 | 0.146 | 0.019 | 0.024 |
ANOVA results.
| Variance source | Sum of squares of deviations | Degree of freedom | Variance | F | P |
|---|---|---|---|---|---|
| A | 0.005 | 2 | 0.0025 | 1.00 | |
| B | 0.146 | 2 | 0.073 | 29.20 | <0.05 |
| C | 0.019 | 2 | 0.0095 | 3.80 | |
| D | 0.024 | 2 | 0.012 | 4.80 | |
| Error | 0.005 | 2 | 0.0025 |
Notes: F0.01(2,2) = 99.00; F0.05(2,2) = 19.00.
Results of histopathologic observation.
| Time (weeks) | Model Group (n * = 20) | Treatment Group (n = 20) | Blank Group (n = 4) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal | Inflammation | Paraplasm | Squamous cell carcinoma | Normal | Inflammation | Paraplasm | Squamous cell carcinoma | Normal | |||||
| Mild | Moderate | Severe | Mild | Moderate | Severe | ||||||||
| 3 | 19 | 1 | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 | 0 | 4 |
| 6 | 1 | 10 | 4 | 4 | 1 | 0 | 5 | 10 | 3 | 1 | 1 | 0 | 4 |
| 9 | 1 | 2 | 12 | 1 | 3 | 1 | 4 | 6 | 4 | 5 | 1 | 0 | 4 |
| 12 | 0 | 0 | 5 | 4 | 4 | 7 | 0 | 5 | 4 | 4 | 3 | 4 | 4 |
| Total | 21 | 13 | 21 | 9 | 8 | 8 | 29 | 21 | 11 | 10 | 5 | 4 | 16 |
n = number of samples. Each roman number represent the number of samples.
Different histologic incidences in model and treatment groups.
| State | Model Group | Treatment Group |
|---|---|---|
| Normal | 21 | 29 |
| Inflammation | 13 | 21 |
| Paraplasm | 38 | 26 |
| Squamous cell carcinoma | 8 | 4 |
Each roman number represent the number of samples.
VEGF positive expression rates in model and treatment groups.
| State | Model Group | Treatment Group | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Positive rate (%) | Grade 0 | Grade 1 | Grade 2 | Positive rate (%) | |
| Normal | 8 | 0 | 0 | 0 | 18 | 0 | 0 | 0 |
| Inflammation | 9 | 6 | 4 | 52.6 | 17 | 10 | 2 | 41.4 |
| Paraplasm | 9 | 10 | 26 | 80.0 | 14 | 11 | 4 | 51.7 |
| Squamous cell carcinoma | 1 | 2 | 5 | 87.5 | 1 | 2 | 1 | 75 |
Comparison of rates of two samples for intra-group comparison, and rank-sum test for inter-group comparison. Each roman number represent the number of samples.
Figure 3(a). Tissue sections at 9 weeks in the Treatment Group; (b). Tissue sections at 9 weeks in the Model Group; (c). Tissue sections at 12 weeks in the Treatment Group; (d). Tissue sections at 12 weeks in the Model Group.
Figure 4Tissue sections at 9 weeks corresponds VEGF immunostaining. (a). Dysplasia epithelium in the Treatment Group; (b). Dysplasia epithelium in the Model Group; (c). Squamous cell carcinoma in the Treatment Group; (d). Squamous cell carcinoma epithelium in the Model Group.
Caspase-3 positive expression rates in model and treatment groups.
| State | Model Group | Treatment Group | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Positive Rate (%) | Grade 0 | Grade 1 | Grade 2 | Positive Rate (%) | |
| Normal | 4 | 4 | 0 | 50 | 13 | 5 | 0 | 27.8 |
| Inflammation | 8 | 7 | 4 | 57.9 | 15 | 10 | 4 | 48.3 |
| Paraplasm | 11 | 11 | 23 | 75.6 | 14 | 10 | 5 | 51.7 |
| Squamous cell carcinoma | 1 | 1 | 6 | 87.5 | 2 | 1 | 1 | 50 |
Comparison of rates of two samples for intra-group comparison, and rank-sum test for inter-group comparison. Each roman number represent the number of samples.
Figure 5Tissue sections at 9 weeks corresponds caspase-3 immunostaining. (a). Dysplasia epithelium in the Treatment Group; (b). Dysplasia epithelium in the Model Group; (c). Squamous cell carcinoma the Treatment Group; (d). Squamous cell carcinoma epithelium in the Model Group.
Group allocation and disposition of test animals.
| Group | Number | Disposition |
|---|---|---|
| Blank | 8 | After 3 weeks of breeding, apply normal saline to bilateral cheek membranes, and give 0.5% sodium carboxymethyl cellulose. 2 animals each are sacrificed at weeks 3, 6, 9 and 12. |
| Model | 40 | After 3 weeks of breeding, apply DMBA to bilateral cheek membranes, and give 0.5% sodium carboxymethyl cellulose. 10 animals each are sacrificed at weeks 3, 6, 9 and 12. |
| Treatment | 40 | After 3 weeks of breeding, apply DMBA to bilateral cheek membranes, and give ganoderma triterpenes drug liquid. 10 animals each are sacrificed at weeks 3, 6, 9 and 12. |